Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space - 2Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- 3What to know about voluntary chocolate recall
- 4Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks
- 52024 Eurovision winner Nemo returns trophy over Israel's participation
- Pick Your #1 Kind Of Treat
- Merz visit highlights new strategic, and strained, Germany-Israel bond
- Boeing's troubled capsule won't carry astronauts on next space station flight
- New ‘Cloud-9’ object could reveal the secrets of dark matter
- Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- New research reveals urban raccoons across the US show early signs of domestication
- From White Elephant to Favorite Things parties, here are all the rules you need to know every kind of gift exchange
- Wonderful Sea shores All over the Planet
- 'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
